Course Overview
This enduring material presents an update on selected topics in cardiology, highlighting areas of controversy, areas of recent advancement, and areas of particular interest to clinicians. The original program provided interactivity with registrants who had the opportunity to pose questions in advance of the symposium. Selected questions were addressed during the program.

Educational Objectives
The intended result of this activity is increased knowledge. At the conclusion of this program, participants will be able to

• Comprehend the full importance of diabetes and metabolic syndrome as contributing factors to cardiovascular disease.
• Summarize recent scientific advances and clinical guidelines for lipids management.
• Discuss the role of CT angiography in current practice.
• Critically evaluate modern therapies for the treatment of peripheral vascular disease.
• Provide perspective on how the treatment of ACS has evolved over the last decade.
• Discuss the past, present, and future roles of biomarkers in cardiovascular disease management.
• Highlight recent advances in the treatment of CHF.
• Summarize recent scientific information and guidelines for the use of implantable defibrillators.
• Discuss recent advances in percutaneous coronary intervention.
• Summarize recent CV surgical techniques and advances.
• Provide an update on recent advances in stem cell therapy and discuss its use in the management of heart failure.

Target Audience
This enduring material is intended for cardiologists, cardiovascular surgeons, clinical researchers, sub-specialty trainees, nurses, and hospital administrators. 

Evaluation / Feedback
We value your comments; please send your suggestions and comments to the office of continuing medical education at the Texas Heart Institute.

Accreditation Statement
Texas Heart Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Texas Heart Institute no longer designates this educational activity for credit.

The estimated time to complete this activity, including review of the materials is 3.5 hours.

Term of Approval
March 2006 through March 2009. Original release date: March 31, 2006.

Peer Review
In March 2006, this continuing medical education activity was reviewed by Patrick Hogan, MD, Texas Heart Institute, Houston, TX. In order to ensure the continued relevance of this activity it was reviewed again by Dr. Ferguson in August 2007.

Disclosure of Relationships
Each Faculty disclosure statement is posted in the individual slide presentation.

It is the intent of the Texas Heart Institute to assure that its educational mission and its continuing medical activities in particular, should not be influenced by the special interests of individuals associated with its program.  The Institute’s policy requires that the activity director, planning committee, and faculty disclose all relationships with commercial interests.  Faculty is also required to disclose any discussion of unlabeled use or investigational use of pharmaceutical and medical device products. When discussing therapeutic options, the presenter should use generic names.  If it is necessary to use a trade name, then those of several companies should be used.

In accordance with the guidelines of the Accreditation Council for Continuing Medical Education, these faculty members have disclosed the following relationships with either one or more of the manufacturers of commercial products discussed or with either one or more of the corporate organizations offering educational grants for this continuing medical education activity.

All disclosures are indicated in individual presentations.

Return to event home page.